UBS Group’s Aravive, Inc. Common Stock ARAV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-70,600
| Closed | -$8.75K | – | 10410 |
|
|
2023
Q4 | $8.75K | Sell |
70,600
-110,982
| -61% | -$15.2K | ﹤0.01% | 7529 |
|
|
2023
Q3 | $24K | Buy |
181,582
+95,987
| +112% | +$60.3K | ﹤0.01% | 6708 |
|
|
2023
Q2 | $108K | Buy |
85,595
+53,581
| +167% | +$86.9K | ﹤0.01% | 5956 |
|
|
2023
Q1 | $64K | Buy |
32,014
+6,014
| +23% | +$11.3K | ﹤0.01% | 6262 |
|
|
2022
Q4 | $34.3K | Hold |
26,000
| – | – | ﹤0.01% | 7105 |
|
|
2022
Q3 | $21K | Hold |
26,000
| – | – | ﹤0.01% | 7358 |
|
|
2022
Q2 | $26K | Sell |
26,000
-15,000
| -37% | -$19.8K | ﹤0.01% | 6576 |
|
|
2022
Q1 | $79K | Sell |
41,000
-9,695
| -19% | -$20.9K | ﹤0.01% | 6077 |
|
|
2021
Q4 | $111K | Sell |
50,695
-7,545
| -13% | -$25.1K | ﹤0.01% | 6226 |
|
|
2021
Q3 | $217K | Sell |
58,240
-13,813
| -19% | -$59K | ﹤0.01% | 5253 |
|
|
2021
Q2 | $431K | Sell |
72,053
-5,167
| -7% | -$27.3K | ﹤0.01% | 4843 |
|
|
2021
Q1 | $509K | Buy |
77,220
+2,529
| +3% | +$16.6K | ﹤0.01% | 4855 |
|
|
2020
Q4 | $421K | Buy |
74,691
+1,606
| +2% | +$8.81K | ﹤0.01% | 4733 |
|
|
2020
Q3 | $343K | Sell |
73,085
-7,842
| -10% | -$55.7K | ﹤0.01% | 4456 |
|
|
2020
Q2 | $942K | Buy |
80,927
+1,083
| +1% | +$12.8K | ﹤0.01% | 3559 |
|
|
2020
Q1 | $460K | Sell |
79,844
-2,112
| -3% | -$18.9K | ﹤0.01% | 4048 |
|
|
2019
Q4 | $1.12M | Buy |
81,956
+15,952
| +24% | +$141K | ﹤0.01% | 4101 |
|
|
2019
Q3 | $495K | Sell |
66,004
-1,714
| -3% | -$10.7K | ﹤0.01% | 4574 |
|
|
2019
Q2 | $406K | Buy |
67,718
+11,814
| +21% | +$73.7K | ﹤0.01% | 4446 |
|
|
2019
Q1 | $394K | Buy |
55,904
+22,363
| +67% | +$117K | ﹤0.01% | 4200 |
|
|
2018
Q4 | $118K | Buy |
33,541
+27,955
| +500% | +$161K | ﹤0.01% | 5400 |
|
|
2018
Q3 | $47K | Buy |
5,586
+2,537
| +83% | +$26.7K | ﹤0.01% | 6207 |
|
|
2018
Q2 | $37K | Buy |
3,049
+1,799
| +144% | +$18.5K | ﹤0.01% | 6237 |
|
|
2018
Q1 | $12K | Sell |
1,250
-166
| -12% | -$1.87K | ﹤0.01% | 6774 |
|
|
2017
Q4 | $19K | Sell |
1,416
-1,517
| -52% | -$19.5K | ﹤0.01% | 6602 |
|
|
2017
Q3 | $43K | Buy |
2,933
+5
| +0.2% | +$504 | ﹤0.01% | 5900 |
|
|
2017
Q2 | $307K | Buy |
2,928
+66
| +2% | +$7.09K | ﹤0.01% | 4469 |
|
|
2017
Q1 | $367K | Buy |
+2,862
| New | +$302K | ﹤0.01% | 4259 |
|
|
2016
Q4 | – | Sell |
-163
| Closed | -$12K | – | 8116 |
|
|
2016
Q3 | $12K | Buy |
163
+30
| +23% | +$2.17K | ﹤0.01% | 6673 |
|
|
2016
Q2 | $9K | Hold |
133
| – | – | ﹤0.01% | 6853 |
|
|
2016
Q1 | $6K | Sell |
133
-110
| -45% | -$5.83K | ﹤0.01% | 6947 |
|
|
2015
Q4 | $18K | Sell |
243
-285
| -54% | -$19.1K | ﹤0.01% | 6872 |
|
|
2015
Q3 | $36K | Buy |
528
+395
| +297% | +$37.1K | ﹤0.01% | 6118 |
|
|
2015
Q2 | $12K | Sell |
133
-67
| -34% | -$6.79K | ﹤0.01% | 7330 |
|
|
2015
Q1 | $22K | Buy |
200
+155
| +344% | +$18.2K | ﹤0.01% | 6904 |
|
|
2014
Q4 | $6K | Buy |
+45
| New | +$5.26K | ﹤0.01% | 8870 |
|
Other funds holding ARAV
UBS Group's ARAV Position: Q1 2024 in Review
UBS Group sold out of Aravive, Inc. Common Stock (ARAV) in Q1 2024, closing a stake of 70,600 shares — an estimated $8.75K sold.
UBS Group first reported a position in ARAV in Q4 2014 and held it in 36 quarters. The position peaked at $1.12M in Q4 2019. 3 funds tracked by Wall St. Rank hold ARAV as of Q1 2024.
- UBS Group reported no remaining Aravive, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- UBS Group sold 70,600 Aravive, Inc. Common Stock shares in Q1 2024, an estimated $8.75K.
- UBS Group first reported a position in Aravive, Inc. Common Stock in Q4 2014 and held it in 36 quarters.
- UBS Group's Aravive, Inc. Common Stock position peaked at $1.12M in Q4 2019.
- 3 funds tracked by Wall St. Rank held Aravive, Inc. Common Stock as of Q1 2024.
Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.